RxDoctor Payments Data

Jennifer Huang, MD

Ophthalmology · Monterey Park, CANPI 1316149735

Payments from drug & device makers

$4,054in general payments, 2019–2025

Across 60 payments — averaging $67.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$2K
  • Alcon$769
  • Bausch & Lomb Americas Inc.$243
  • Aerie Pharmaceuticals, Inc.$239
  • Sight Sciences, Inc.$192
  • AbbVie$173
  • plus $814 from 12 others

What the payments were for

  • Consulting fees$1,62440%
  • Food & beverage$2,43060%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,054 in reported general payments places this provider in the 70th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$191,193
Medicare patients
445
Services billed
1,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine111$105,159
Cyclosporine127$73,282
LumiganBimatoprost180$66,287
RhopressaNetarsudil Mesylate129$46,829
RocklatanNetarsudil Mesylat/Latanoprost86$43,065
Brimonidine Tartrate618$19,261
Alphagan PBrimonidine Tartrate46$18,491
Latanoprost1,854$17,495
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat751$16,773
XiidraLifitegrast11$14,497
Prednisolone Acetate349$13,453
Timolol Maleate517$10,519
SimbrinzaBrinzolamide/Brimonidine Tart41$10,461
CombiganBrimonidine Tartrate/Timolol30$10,324
XalatanLatanoprost26$7,796

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$173$200,261367 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$239$89,894215 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$243$21,30837 claims
AlconSimbrinza$769$10,46141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Monterey Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →